Make it or break it for BIOASIS TECHNOLOGIES in 2020

The entity current chance of distress is over 77.0 percent. Let's try to go over BIOASIS (BIOAF) outlook for August. Will BIOASIS TECHNOLOGIES executives continue to add value? We are able to interpolate and collect twenty-nine available fundamental indicators for BIOASIS TECHNOLOGIES INC, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all BIOASIS TECHNOLOGIES INC financials, including its price to sales, cash per share, beta, as well as the relationship between the ebitda and short ratio . As BIOASIS TECHNOLOGIES INC appears to be a penny stock we also recommend to validate its price to book numbers. Use BIOASIS TECHNOLOGIES to enhance returns of your portfolios. The stock experiences a very speculative upward sentiment. The trend is possibly hyped up. Check odds of BIOASIS TECHNOLOGIES to be traded at $0.3125 in 30 days.
Published over a year ago
View all stories for BiOasis Technologies | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Gabriel Shpitalnik

BIOASIS TECHNOLOGIES has a beta of -0.1552. Let's try to break down what BIOASIS's beta means in this case. As returns on the market increase, BIOASIS TECHNOLOGIES returns are expected to increase less than the market. However, during the bear market, the loss on holding BIOASIS TECHNOLOGIES will be expected to be smaller as well. The beta indicator helps investors understand whether BIOASIS TECHNOLOGIES moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if BIOASIS deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. BIOASIS TECHNOLOGIES holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.1552, which signifies not very significant volatility relative to the market. Let's try to break down what BIOASIS's beta means in this case. As returns on the market increase, returns on owning BIOASIS TECHNOLOGIES are expected to decrease at a much lower rate. During the bear market, BIOASIS TECHNOLOGIES is likely to outperform the market. Although it is essential to pay attention to BIOASIS TECHNOLOGIES INC historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy towards foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if BIOASIS TECHNOLOGIES INC expected return of 1.51 will be sustainable into the future, we have found twenty-one different technical indicators, which can help you to check if the expected returns are sustainable. Use BIOASIS TECHNOLOGIES information ratio and the relationship between the maximum drawdown and skewness to analyze future returns on BIOASIS TECHNOLOGIES.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as BiOasis Technologies. Regardless of method or technology, to accurately forecast the stock or bond market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for BiOasis Technologies

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of BiOasis Technologies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of BiOasis Technologies in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as BiOasis Technologies. Your research has to be compared to or analyzed against BiOasis Technologies' peers to derive any actionable benefits. When done correctly, BiOasis Technologies' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in BiOasis Technologies.

Watch out for price decline

Please consider monitoring BiOasis Technologies on a daily basis if you are holding a position in it. BiOasis Technologies is trading at a penny-stock level, and the possibility of delisting is much higher compared to other pink sheets. However, just because the pink sheet is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as BiOasis Technologies stock to be traded above the $1 level to remain listed. If BiOasis Technologies pink sheet price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is BiOasis Technologies's Liquidity

BiOasis Technologies financial leverage refers to using borrowed capital as a funding source to finance BiOasis Technologies ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. BiOasis Technologies financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to BiOasis Technologies' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of BiOasis Technologies' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between BiOasis Technologies's total debt and its cash.

Breaking down BiOasis Technologies Indicators

BIOASIS TECHNOLOGIES defends 15.43 m market capitalization. The firm reported revenue of 205.98 K. Net Loss for the year was (4.59 M) with profit before overhead, payroll, taxes, and interest of 606.38 K. BIOASIS TECHNOLOGIES INC is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about BIOASIS TECHNOLOGIES implied risk. BIOASIS TECHNOLOGIES INC is a potential penny stock. Although BIOASIS TECHNOLOGIES may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand upside potential and downside risk of investing in BIOASIS TECHNOLOGIES INC. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings,sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that has been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The one and only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Are BIOASIS TECHNOLOGIES technical ratios showing a recoup?

Latest downside deviation is at 9.97. BIOASIS TECHNOLOGIES INC is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about BIOASIS TECHNOLOGIES implied risk. BIOASIS TECHNOLOGIES INC is a potential penny stock. Although BIOASIS TECHNOLOGIES may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand upside potential and downside risk of investing in BIOASIS TECHNOLOGIES INC. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings,sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that has been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The one and only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

The Current Take On BIOASIS TECHNOLOGIES Investment

While many of the other players under biotechnology industry are still a little expensive, even after the recent corrections, BIOASIS TECHNOLOGIES may offer a potential longer-term growth to investors. All things considered, as of 5th of July 2020, we believe that BIOASIS TECHNOLOGIES is currently overvalued with high chance of financial distress in the next two years. Our prevailing 30 days buy/sell recommendation on the firm is Strong Sell. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to drop some or all of your BIOASIS TECHNOLOGIES holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to BIOASIS TECHNOLOGIES.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of BiOasis Technologies. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com